Clinical Trial Update: A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept trial is evaluating itepekimab, an anti-IL-33 monoclonal antibody, for efficacy, safety, and tolerability in adults with chronic rhin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhinosinusitis Without Nasal Polyps

Drugs mentioned

• itepekimab (itepekimab)

Snippet

Sponsor: Sanofi | Conditions: Chronic Rhinosinusitis Without Nasal Polyps | Phase 2 | Status: ACTIVE_NOT_RECRUITING